Apax Partners to acquire the operating subsidiaries of Invent Farma

Invent Farma develops, manufactures and markets generic drugs.

The transaction is expected to close in the next few months. Terms of the transaction were not disclosed.

Located in Barcelona, Invent Farma develops, manufactures and markets generic drugs. It owns and operates manufacturing plants in Spain and comprises three divisions:

• Inke, a manufacturer of APIs, which has a unique expertise in the respiratory area

• Lesvi, a highly flexible manufacturer of finished dosage forms, which has capabilities across multiple therapeutic areas

• Qualigen, which markets generic drugs in Spain and has a leading and rapidly growing franchise in the central nervous system field.

Steven Dyson, Partner and Co-Head of Healthcare at Apax Partners, said: “We have identified the European generics space as an attractive investment area. We are excited to build on Invent Farma’s success, particularly on their strength in respiratory APIs and their outstanding CNS franchise. We will look to support the organic growth of Invent Farma as well as further consolidate the European generics market, as evidenced by our recent announcement of a transaction with Germany’s neuraxpharm.”

Friðrik Steinn Kristjánsson, chairman of Invent Farma and owner of Silfurberg said: “We are very proud of Invent Farma's achievements in Spain, Europe and globally across all of its three business units, namely Inke, Lesvi, and Qualigen. On behalf of the Shareholders, I would like to thank the management and employees of Invent for their dedication, commitment and expertise, which led to the Company performing very well under our ownership with significant revenue and profit growth."

Commenting on the transaction, Ervin Veszprémi, CEO of Invent Farma: "We want to thank our previous shareholders for their continued support offered during all these years. We are delighted to be partnering with Apax. With their experience in both healthcare and 'buy-and-build' strategies, they will provide invaluable expertise and investment as we enter this next phase of growth."